NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
Key Points
- FDA Review Outcome: NeuroPace has received communication from the U.S. Food and Drug Administration (FDA) regarding its Premarket Approval (PMA) Supplement seeking to expand the labeled indication for the RNS® System to include patients with antiseizure medication-resistant idiopathic generalized epilepsy (IGE). The FDA determined that the PMA Supplement is not approvable in its current form.
- Additional Data Required: The FDA requested further clinical evidence, specifically additional data from NeuroPace’s NAUTILUS trial and supporting literature.
- Active Dialogue with FDA: NeuroPace will submit a Submission Issue Request (SIR) and intends to work closely with the FDA to amend its application with supplemental information and context, especially regarding the patient populations evaluated in NAUTILUS.
- Management Response: NeuroPace’s CEO Joel Becker expressed optimism, noting that while initial approval was not granted, the FDA is engaging actively and collaboratively to address outstanding questions. The company is working diligently to provide the necessary information for eventual approval.
- NAUTILUS Study Results: The PMA Supplement is supported by robust Level 1 evidence from the NAUTILUS trial, which is the first randomized controlled study of neuromodulation in drug-resistant IGE. At 18 months, patients treated with the RNS System experienced a 77% median reduction in generalized tonic-clonic (GTC) seizures, and 40% achieved GTC seizure freedom. The study also showed rapid reductions in other seizure types.
- 24-Month Data Strength: Further supporting data provided to the FDA showed that patients who received stimulation for 23 of 24 months post-implant achieved a 100% median reduction in GTC seizures, highlighting durable benefits in a population with no approved neuromodulation or surgical options.
- Unmet Medical Need: NeuroPace’s Chief Medical Officer, Dr. Martha Morrell, emphasized that patients with drug-resistant IGE often live with uncontrolled seizures for many years, are not candidates for surgery, and currently have no approved neuromodulation devices. The rapid enrollment in the NAUTILUS study underscores the demand for better treatments.
- Financial Guidance: NeuroPace’s management guidance does not include any contribution from the expanded IGE indication. Updates to financial outlook will be provided on the Q2 2026 earnings call scheduled for August 11, 2026.
- Investor Call: NeuroPace will host a conference call at 4:30 p.m. Eastern Time to discuss these developments. The webcast will be available for replay for at least 90 days on NeuroPace’s investor relations website.
Implications for Shareholders
- Regulatory Setback: The FDA’s non-approval of the PMA Supplement in its current form is a significant event. While not an outright rejection, it delays potential market expansion for the RNS System into drug-resistant IGE, a large and underserved patient population.
- Ongoing Collaboration: NeuroPace’s continued dialogue and constructive relationship with the FDA may mitigate concerns. The company is actively working to resolve outstanding issues, which could lead to approval in the future.
- Clinical Data Strength: The NAUTILUS study’s published and peer-reviewed results provide strong evidence for the efficacy of the RNS System in drug-resistant IGE. If the FDA ultimately approves the indication expansion, it could unlock significant commercial opportunities and drive share value.
- Financial Impact: Management has not included revenues from the IGE indication in its current guidance. Investors should watch for updates on the August 11 earnings call, as any change in regulatory status or outlook could materially affect future financial performance.
- Potential Share Price Movement: The news is both potentially negative (delay in approval) and positive (strong clinical data and collaborative FDA stance), making it highly price-sensitive. Investors should monitor further FDA communications and NeuroPace’s actions closely.
About NeuroPace
NeuroPace is a Mountain View, California-based medical device company specializing in innovative solutions for epilepsy. Its RNS System is the first and only commercially available, brain-responsive platform for personalized, real-time treatment at the seizure source. The company aims to set a new standard of care for drug-resistant epilepsy and potentially other brain disorders through its technology.
Conference Call Details
Time: 4:30 p.m. Eastern Time
Phone Access: +1 (800) 715-9871, Conference ID 8467256
Webcast: NeuroPace Investor Relations Events (Replay available for at least 90 days)
Disclaimer
This article contains forward-looking statements based on current information and expectations. Actual results may differ materially due to risks involving regulatory approvals, market acceptance, and other factors. Investors should review NeuroPace’s filings with the SEC and consult their financial advisors before making investment decisions. The author assumes no responsibility for actions taken based on this article.
